Long-term (52-week) efficacy and safety of ipragliflozin add-on therapy to insulin in Japanese patients with type 1 diabetes mellitus: An uncontrolled, open-label extension of a phase III study.
Kohei KakuHiroyuki IsakaTaishi SakataniJunko ToyoshimaPublished in: Journal of diabetes investigation (2020)
The efficacy and safety of 50 mg, once-daily ipragliflozin in insulin-treated type 1 diabetes mellitus patients were confirmed in this long-term, open-label extension study. No safety concerns were attributed to a dose increase to 100 mg.
Keyphrases
- open label
- phase iii
- clinical trial
- type diabetes
- phase ii
- end stage renal disease
- glycemic control
- newly diagnosed
- chronic kidney disease
- ejection fraction
- randomized controlled trial
- phase ii study
- study protocol
- physical activity
- cardiovascular disease
- squamous cell carcinoma
- stem cells
- radiation therapy
- patient reported outcomes
- placebo controlled
- metabolic syndrome
- skeletal muscle